Published • loading... • Updated
EMA Fast-Tracks Review of Revolutions’ Experimental Pancreatic Cancer Pill
The review follows Phase 3 results showing improved overall and progression-free survival versus chemotherapy in previously treated metastatic pancreatic cancer patients.
- On Tuesday, the European Medicines Agency initiated a phased review of Revolution Medicines' experimental treatment, daraxonrasib, for patients with metastatic pancreatic cancer.
- This assessment follows "unprecedented" results from the pivotal Phase 3 RASolute 302 trial, which demonstrated significant improvements in overall and progression-free survival compared to standard cytotoxic chemotherapy.
- Patients with metastatic pancreatic ductal adenocarcinoma face limited therapeutic options, with the EMA noting a "poor prognosis" and a life expectancy of about six months after disease progression.
- The phased review process allows regulators to evaluate quality, safety, and efficacy data as they become available, potentially shortening the assessment timeline compared to conventional marketing applications.
- Concurrently, Revolution Medicines is completing a rolling New Drug Application submission to the U.S. Food and Drug Administration under the Commissioner's National Priority Voucher pilot program.
Insights by Ground AI
16 Articles
16 Articles
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
·New York, United States
Read Full Article
European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process
Phased review by EMA aims to accelerate assessment of company’s investigational drug daraxonrasib in pancreatic cancer based on unprecedented clinical results from pivotal Phase 3 RASolute 302 trial Rolling submission of NDA for daraxonrasib to U.S. FDA under Commissioner’s National Priority Voucher pilot program nearing completion REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — […]
·Canada
Read Full Article
Cambridge Times+6 Reposted by 6 other sources
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Phased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented clinical results from pivotal Phase 3 RASolute 302 trial
·Cambridge, Canada
Read Full Article
Coverage Details
Total News Sources16
Leaning Left5Leaning Right3Center3Last UpdatedBias Distribution46% Left
Bias Distribution
- 46% of the sources lean Left
46% Left
L 46%
C 27%
R 27%
Factuality
To view factuality data please Upgrade to Premium
